US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5756747A
(en)
|
1989-02-27 |
1998-05-26 |
Riker Laboratories, Inc. |
1H-imidazo 4,5-c!quinolin-4-amines
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
JPH09500128A
(ja)
|
1993-07-15 |
1997-01-07 |
ミネソタ マイニング アンド マニュファクチャリング カンパニー |
イミダゾ〔4,5−c〕ピリジン−4−アミン
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
CA2194761C
(en)
|
1994-07-15 |
2006-12-19 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
ES2232871T3
(es)
|
1996-07-03 |
2005-06-01 |
Sumitomo Pharmaceuticals Company, Limited |
Nuevos derivados de purina.
|
US6387938B1
(en)
|
1996-07-05 |
2002-05-14 |
Mochida Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
JP4101302B2
(ja)
|
1997-01-09 |
2008-06-18 |
テルモ株式会社 |
新規アミド誘導体および合成中間体
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
EP1003531B1
(en)
|
1997-05-20 |
2007-08-22 |
Ottawa Health Research Institute |
Processes for preparing nucleic acid constructs
|
US6329381B1
(en)
|
1997-11-28 |
2001-12-11 |
Sumitomo Pharmaceuticals Company, Limited |
Heterocyclic compounds
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
TW572758B
(en)
|
1997-12-22 |
2004-01-21 |
Sumitomo Pharma |
Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(ja)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h―イミダゾピリジン誘導体
|
WO2000075304A1
(fr)
|
1999-06-08 |
2000-12-14 |
Aventis Pasteur |
Oligonucleotide immunostimulant
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
EP2314693A3
(en)
|
1999-08-13 |
2012-11-28 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
US6651132B1
(en)
|
2000-07-17 |
2003-11-18 |
Microsoft Corporation |
System and method for emulating the operation of a translation look-aside buffer
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
SG177000A1
(en)
|
2001-08-17 |
2012-01-30 |
Coley Pharm Gmbh |
Combination motif immune stimulatory oligonucleotides with improved activity
|
CN101033242A
(zh)
|
2001-11-27 |
2007-09-12 |
安那迪斯药品股份有限公司 |
3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6525028B1
(en)
|
2002-02-04 |
2003-02-25 |
Corixa Corporation |
Immunoeffector compounds
|
MXPA04012199A
(es)
|
2002-06-07 |
2005-02-25 |
3M Innovative Properties Co |
Imidazopiridinas sustituidas con eter.
|
EP1545597B1
(en)
|
2002-08-15 |
2010-11-17 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
AU2003299082A1
(en)
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
EP1605943A4
(en)
|
2003-03-07 |
2008-01-16 |
3M Innovative Properties Co |
1-AMINO-1H-imidazoquinolines
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
TW200510412A
(en)
|
2003-08-12 |
2005-03-16 |
3M Innovative Properties Co |
Oxime substituted imidazo-containing compounds
|
CA2536136C
(en)
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
JP5043435B2
(ja)
|
2003-10-03 |
2012-10-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
アルコキシ置換イミダゾキノリン
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
NZ546274A
(en)
|
2003-10-03 |
2009-12-24 |
3M Innovative Properties Co |
Pyrazolopyridines and analags thereof
|
AU2004291122A1
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
CN1906193A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
肟取代的咪唑环化合物
|
AR046781A1
(es)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
Derivados de imidazoquinolinas. composiciones farmaceuticas.
|
EP1686992A4
(en)
|
2003-11-25 |
2009-11-04 |
3M Innovative Properties Co |
HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
|
WO2005076783A2
(en)
|
2003-12-04 |
2005-08-25 |
3M Innovative Properties Company |
Sulfone substituted imidazo ring ethers
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
CA2552101A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
WO2005066169A2
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US20080015184A1
(en)
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006009832A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
EP1765348B1
(en)
|
2004-06-18 |
2016-08-03 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006093514A2
(en)
|
2004-06-18 |
2006-09-08 |
3M Innovative Properties Company |
Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
|
AU2005282726B2
(en)
|
2004-09-02 |
2011-06-02 |
3M Innovative Properties Company |
1-alkoxy 1H-imidazo ring systems and methods
|
US20090270443A1
(en)
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
AU2005282523A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1H imidazo ring systems and methods
|
WO2006028451A1
(en)
|
2004-09-03 |
2006-03-16 |
3M Innovative Properties Company |
1-amino 1-h-imidazoquinolines
|
WO2006074003A2
(en)
|
2004-12-30 |
2006-07-13 |
3M Innovative Properties Company |
CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
|
US8034938B2
(en)
|
2004-12-30 |
2011-10-11 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
AU2006212765B2
(en)
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
CA2597446A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
AU2006213745A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
|
JP2008530113A
(ja)
|
2005-02-11 |
2008-08-07 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
オキシムおよびヒドロキシラミン置換イミダゾ[4,5−c]環化合物および方法
|
AU2006216799A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazonaphthyridines
|
JP2008531567A
(ja)
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ヒドロキシアルキル置換イミダゾキノリン化合物および方法
|
AU2006216686A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
US8178677B2
(en)
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
EP2190440A1
(en)
|
2007-08-13 |
2010-06-02 |
Pfizer Inc. |
Combination motif immune stimulatory oligonucleotides with improved activity
|
CN101918447B
(zh)
|
2007-12-14 |
2014-06-11 |
布里斯托尔-米尔斯·斯奎布公司 |
人ox40受体的结合分子
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
AU2009205665B2
(en)
|
2008-01-15 |
2013-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for manipulating phagocytosis mediated by CD47
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
EP2927244A1
(en)
*
|
2008-09-19 |
2015-10-07 |
MedImmune, LLC |
Antibodies directed to DLL4 and uses thereof
|
US8552165B2
(en)
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
SI2780039T1
(en)
|
2011-11-17 |
2018-06-29 |
Pfizer Inc. |
Cytotoxic peptides and their conjugates between the antibody and the drug
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
JP6392770B2
(ja)
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗cd47抗体およびその使用方法
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
AU2014238105B2
(en)
|
2013-03-15 |
2018-11-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for achieving therapeutically effective doses of anti-CD47 agents
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
SG11201609707WA
(en)
|
2014-07-01 |
2017-01-27 |
Pfizer |
Bispecific heterodimeric diabodies and uses thereof
|
US9501570B2
(en)
|
2014-07-14 |
2016-11-22 |
Verizon Patent And Licensing Inc. |
Dynamic routing system
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9719791B2
(en)
|
2014-12-10 |
2017-08-01 |
Mapquest, Inc. |
Computerized systems and methods for providing travel information and/or content to users
|
JP6959865B2
(ja)
|
2015-01-21 |
2021-11-05 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ
|
CN114773476A
(zh)
|
2015-04-13 |
2022-07-22 |
辉瑞公司 |
治疗性抗体和它们的用途
|
PT3341015T
(pt)
|
2015-08-26 |
2021-10-12 |
Univ Leland Stanford Junior |
Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária
|
NZ740686A
(en)
|
2015-09-18 |
2021-12-24 |
Arch Oncology Inc |
Therapeutic cd47 antibodies
|
CN114716552A
(zh)
|
2016-01-11 |
2022-07-08 |
四十七公司 |
人源化、小鼠或嵌合抗cd47单克隆抗体
|
AU2017210224B2
(en)
|
2016-01-21 |
2024-02-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with combinations of immunoregulatory agents
|
EP3442541B1
(en)
|
2016-04-10 |
2021-11-17 |
Georgia State University Research Foundation, Inc. |
Composition for use in treating cancer
|
AU2017250809B2
(en)
|
2016-04-15 |
2024-02-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
|
US20200255515A1
(en)
|
2016-05-09 |
2020-08-13 |
Celgene Corporation |
Cd47 antibodies and methods of use thereof
|
GEP20217234B
(en)
|
2016-08-15 |
2021-03-25 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
WO2018075960A1
(en)
|
2016-10-21 |
2018-04-26 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
WO2018137705A1
(en)
|
2017-01-26 |
2018-08-02 |
Zai Lab (Shanghai) Co., Ltd. |
Cd47 antigen binding unit and uses thereof
|
EP3592387A4
(en)
|
2017-03-09 |
2021-03-31 |
The Board of Trustees of the Leland Stanford Junior University |
TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING THE CD47 SIGNAL PATH
|
CA3057139A1
(en)
|
2017-03-22 |
2018-09-27 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
CN110958888A
(zh)
|
2017-03-28 |
2020-04-03 |
延龄草治疗公司 |
Cd47阻断疗法
|
CN108864290B
(zh)
|
2017-05-08 |
2021-12-07 |
上海津曼特生物科技有限公司 |
双特异性重组蛋白及其应用
|
WO2018215835A1
(en)
*
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
EP3630835A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
EP3630841A1
(en)
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
CN113896797B
(zh)
*
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
EA039662B1
(ru)
*
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
ES2938652T3
(es)
|
2017-10-18 |
2023-04-13 |
Forty Seven Inc |
Tratamiento del cáncer de ovario con anti-CD47 y anti-PD-L1
|
EP3697817B1
(en)
|
2017-10-18 |
2022-10-05 |
Forty Seven, Inc. |
Anti-cd47 agent-based ovarian cancer therapy
|
CA3084391C
(en)
|
2017-11-20 |
2023-10-10 |
Taizhou Mabtech Pharmaceutical Co., Ltd |
A bifunctional fusion protein targeting cd47 and pd-l1
|
KR20200093639A
(ko)
|
2017-12-04 |
2020-08-05 |
북경한미약품 유한공사 |
천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조
|
WO2019144895A1
(en)
|
2018-01-24 |
2019-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Anti-cd47 antibodies that do not cause significant red blood cell agglutination
|
JP7404247B2
(ja)
|
2018-02-01 |
2023-12-25 |
ファイザー・インク |
Cd70を標的とするキメラ抗原受容体
|
CN112119099A
(zh)
|
2018-03-02 |
2020-12-22 |
Cdr-生物科技股份有限公司 |
三特异性抗原结合蛋白
|
WO2019179434A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/cd47 antibody molecules
|
US20210221908A1
(en)
*
|
2018-06-03 |
2021-07-22 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
AU2019336345A1
(en)
|
2018-09-04 |
2021-04-15 |
Pfizer Inc. |
CD47 blockade with parp inhibition for disease treatment
|
US20210338681A1
(en)
|
2018-10-01 |
2021-11-04 |
Secura Bio, Inc. |
Combination therapies
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
AU2020205100A1
(en)
|
2019-01-04 |
2021-08-19 |
Trio Pharmaceuticals, Inc. |
Multi-specific protein molecules and uses thereof
|
WO2020198370A2
(en)
|
2019-03-25 |
2020-10-01 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
KR20220036998A
(ko)
|
2019-06-25 |
2022-03-23 |
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 |
항 cd47/pd-l1 이중특이성 항체를 포함하는 제제, 이의 제조 방법 및 용도
|